A review of the pharmacologic options for the treatment of alcohol dependence

Formulary

Volumn 42, Issue 1, 2007, Pages 14-31

  Angelini, Michael ^a,b   Brahmbhatt, Yogini ^c  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c Clinical Pharmacy Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; CITALOPRAM; DESIPRAMINE; DISULFIRAM; FLUOXETINE; IMIPRAMINE; INHALATION ANESTHETIC AGENT; METRONIDAZOLE; NALTREXONE; NARCOTIC ANALGESIC AGENT; ONDANSETRON; PHENYTOIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TOPIRAMATE; TRIMETHADIONE; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALCOHOL CONSUMPTION; ALCOHOLISM; ANOREXIA; ANXIETY; ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DECREASED APPETITE; DEPRESSION; DERMATITIS; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ENERGY; FLATULENCE; HEADACHE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; METALLIC TASTE; MONOTHERAPY; NAUSEA; NERVOUSNESS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SUPPORT GROUP; SYNCOPE; SYSTEMATIC REVIEW; TASTE DISORDER; TREATMENT OUTCOME; VOMITING; WEAKNESS;

EID: 33846798238     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238-1245 [erratum in JAMA. 2005;293:293-294].
2. National Institute on Alcohol Abuse and Alcoholism. Tenth Special Report to the U.S. Congress on Alcohol and Health. Rockville, Md: US Department of Health and Human Services; 2000.
3. National Institute on Alcohol Abuse and Alcoholism. Estimated economic costs of alcohol abuse in the United States, 1992 and 1998. Available at: http://www.niaaa.nih.gov/Resources/DatabaseResources/QuickFacts/EconomicData/ cost8.htm.Accessed January 5, 2007.
4. Grant BF. Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey. J Stud Alcohol. 1997;58:464-473.
5. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: National results on adolescent drug use, overview of key findings, 2003. Bethesda, Md: National Institute on Drug Abuse, 2005.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (text revised) (DSM-IV-TR). Washington, DC: American Psychiatric Publishing, 2000.
7. Fleming MF, Mihic SJ, Harris RA. Ethanol. In: Brunton LL, Lazo JS, Parker KL, Buxton I, Blumenthal D, eds. Goodman and Gilman's Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill Professional; 2005:602-603.
8. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56:730-737.
9. Inaba DS, Cohen WE. Downers: Alcohol. In: Uppers, Downers, and All Arounders. 5th ed. Ashland, Ore: CNS Publications, Inc.; 2004:196-200.
10. Szmitko PE, Verma S. Antiatherogenic potential of red wine: clinician update. Am J Physiol Heart Circ Physiol. 2005;288:2023-2030.
11. US Department of Health and Human Services. Helping patients who drink too much: a clinician's guide. Rockville, Md: US Department of Health and Human Services, 2005.
12. National Institute on Alcohol Abuse and Alcoholism. Alcoholism: getting the facts. Available at: http://pubs.niaaa.nih.gov/publications/Getthe Facts_HTML/facts.htm. Accessed January 5, 2007.
13. Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs. 2004;18:485-504.
14. Fuller RK, Hiller-Sturmhofel S. Alcoholism treatment in the United States. An overview. Alcohol Res Health. 1999;23:69-77.
15. Poldrugo F, Haeger DA, Comte S, Walburg J, Palmer AJ. A critical review of pharmacoeconomic studies of acamprosate. Alcohol Alcohol. 2005;40:422-430.
16. Rychlik R, Siedentop H, Pfeil T, Daniel D. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur Addict Res. 2003; 9:59-64.
17. Antabuse [package insert]. East Hanover, NJ: Odyssey Pharmaceuticals Inc. 2003.
18. Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs. 2002;11:491-499.
19. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256:1449-1455.
20. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction. 2004;99:21-24.
21. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18:54-59.
22. Monti PM, Rohsenow DJ, Hutchison KE, et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999;23:1386-1394.
23. Weinrieb RM, O'Brien CP. Naltrexone in the treatment of alcoholism. Annu Rev Med. 1997;48:477-487.
24. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881-887.
25. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21:287-292.
26. Revia [package insert]. Wilmington, Del: DuPont Pharma. 1997.
27. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99:811-828 [erratum in: Addiction. 2005;100:573].
28. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD001867.
29. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130-1135.
30. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
31. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26:1381-1387.
32. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-593.
33. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758-1764.
34. Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27:1142-1149.
35. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res. 2001;25:1634-1647.
36. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96:1565-1573.
37. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176:530-534.
38. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
39. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA; Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
40. Gastpar M, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22:592-598.
41. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996;13:35-39.
42. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry. 1996;53:217-224.
43. Vivitrol [package insert]. Cambridge, Mass: Alkermes Inc. 2006.
44. Garbutt JC, Kranzler HR, O'Malley SS, et al; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-1625 [erratum in: JAMA. 2005;293:1978; JAMA. 2005;293:2864].
45. Kranzler HR, Wesson DR, Billot L; DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004:28:1051-1059.
46. Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res. 2004;28:1356-1361.
47. Campral [package insert]. St Louis, Mo: Forest Pharmaceuticals, Inc. 2004.
48. Doering PL. Substance-related disorders: alcohol, nicotine, and caffeine. In: Pharmacotherapy: A Pathophysiologic Approach. 5th ed. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Stamford, Conn., Appleton & Lange; 2002:1206-1207.
49. Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: Assessment of the pharmacological actions of acamprosate. Prog Neurobiol. 2000;60:343-362.
50. Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol. 1987;4:97-102.
51. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
52. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
53. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
54. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347:1438-1442.
55. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176-187.
56. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003;38:135-141.
57. Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry. 2003;12:144-148.
58. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: A randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol. 2004;65:136-139.
59. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study. Alcohol Alcohol. 2000;35:202-209.
60. Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol. 2003;23:281-293.
61. Anton RF, O'Malley SS, Ciraulo DA, et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
62. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-99.
63. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcohol Clin Exp Res. 1998; 22:573-579.
64. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391-397.
65. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24:1041-1049.
66. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed patients: A randomized controlled trial. JAMA. 2000;284:963-971.
67. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
68. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. Arch Gen Psychiatry. 2004;61:905-912.
69. Kiefer F, Wiedemann K. Combined therapy: What does acamprosate and naltrexone combination tell us? Alcohol Alcohol. 2004;39:542-547.
70. Kenna GA. Pharmacotherapy of alcohol dependence: targeting a complex disorder. Drug Discovery Today: Therapeutic Strategies. 2005;2:71-78.
71. Red Book. 2006 Edition. Montvale, NJ: Thompson PDR; 2006.
72. Red Book Update. October 2006 Edition. Montvale, NJ: Thompson PDR; 2006.